Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis

European Journal of Dermatology

Volumn 22, Issue 3, 2012, Pages 351-357

  Yamada, Daisuke ^a   Asano, Yoshihide ^a   Takahashi, Takehiro ^a   Masui, Yuri ^a   Aozasa, Naohiko ^a   Akamata, Kaname ^a   Noda, Shinji ^a   Tamaki, Zenshiro ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a   Kadono, Takafumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Bosentan; Cyclophosphamide; Decoy receptor 3; Systemic sclerosis; Vasculopathy

Indexed keywords

BOSENTAN; C REACTIVE PROTEIN; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; DECOY RECEPTOR 3; IMMUNOGLOBULIN G;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER ULCER; HEART LEFT VENTRICLE PRESSURE; HUMAN; IMMUNOREGULATION; INTERSTITIAL LUNG DISEASE; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RAYNAUD PHENOMENON; SKIN ULCER; SYSTEMIC SCLEROSIS; TELANGIECTASIA;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COMORBIDITY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 84863196556     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1702     Document Type: Article

References (41)

1. LeRoy EC. Systemic sclerosis (scleroderma). In: Wyngaarden JB, Smith LH, Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders, 1992: 1530-1535.
2. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
3. Zhang J, Salcedo TW, Wan X, et al. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 2001; 107: 1459-68.
4. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-492.
5. Zhai Y, Guo R, Hsu TL, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998; 102: 1142-1151.
6. Yue TL, Ni J, Romanic AM, et al. TL1, a novel tumor necrosis factorlike cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999; 274: 1479-1486.
7. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
8. Lee CS, Hu CY, Tsai HF, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008; 151: 383-390.
9. Hayashi S, Miura Y, Tateishi K, Takahashi M, Kurosaka M. Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis. Mod Rheumatol 2010; 20: 63-68.
10. Bamias G, Kaltsa G, Siakavellas SI, et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010; 137: 242-249.
11. Funke B, Autschbach F, Kim S, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009; 58: 483-491.
12. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001; 61: 2759-2765.
13. Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 2000; 97: 1230-1235.
14. Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 2000; 160: 89-97.
15. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004; 64: 1122-1129.
16. Takahama Y, Yamada Y, Emoto K, et al. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002; 5: 61-68.
17. Macher-Goeppinger S, Aulmann S, Wagener N, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008; 10: 1049-1056.
18. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
19. Preliminary criteria for the classification of systemic sclerosis (scle-roderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-590.
20. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
21. Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.
22. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999; 100: 5-8.
23. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008; 67: 1121-1126.
24. Abraham D. Role of endothelin in lung fibrosis. European Respiratory Review 2008; 17: 145-150.
25. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophos-phamide in patients with systemic sclerosis. Rheumatology (Oxford) 2010; 49: 2375-2380.
26. Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005; 115: 286-294.
27. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011; 10: 276-281.
28. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007; 6: 520-523.
29. Yang M, Chen G, Dang Y, Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci 2010; 115: 232-237.
30. Noda S, Asano Y, Aozasa N, et al. Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2011; 25:1476-1479.
31. Toyama T, Asano Y, Takahashi T, et al. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. J Eur Acad Dermatol Venereol in press.
32. Aozasa N, Asano Y, Akamata K, et al. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. J Eur Acad Dermatol Venereol in press.
33. Taniguchi T, Asano Y, Akamata K, et al. Serum Levels of Galectin-3: Possible Association with Fibrosis, Aberrant Angiogenesis, and Immune Activation in Patients with Systemic Sclerosis. J Rheumatol 2012;39(3):539-544.
34. Hayashi S, Miura Y, Nishiyama T, et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007; 56: 1067-1075.
35. Cambrey AD, Harrison NK, Dawes KE, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994; 11: 439-445.
36. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofi-broblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-2719.
37. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976; 82: 493-512.
38. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006; 297: 333-344.
39. Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010; 59: 153-162.
40. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-1998.
41. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrilloge-nesis in mouse skin. Mol Cell Biol 2009; 29: 425-434.